Delcath: FDA OKs Treatment for Hepatic-Dominant Metastatic Uveal Melanoma

 HEPZATO KIT is the only FDA approved liver-directed therapy to treat metastatic uveal melanoma

Approval includes treatment naïve and previously treated patients and is not limited by HLA genotype

Delcath to hold Business Update Call on August 15, 2023 at 8:00 a.m. Eastern Time

To participate in this event, dial-in approximately 5 to 10 minutes before the beginning of the call.

Event Date: Tuesday, August 15, 2023
Time: 8:00 AM Eastern Time
Participant Numbers: Toll Free: 1-833-630-1960
International: 1-412-317-1841
Webcast: https://app.webinar.net/rE345LOXL6b

CONFERENCE REPLAY
US Toll Free:	1-877-344-7529
International Toll:	1-412-317-0080
Replay Access Code:	4657227
End Date:	August 21, 2023 https://finance.yahoo.com/news/delcath-systems-inc-announces-fda-011000224.html